Effect of acute and sub-chronic administration of the imidazoline compound S 22068 on in vivo glucose and insulin responses in normal lean CBA/Ca mice
| Autor: | Celia A Williams, Peter V. Taberner, Mei-Fen Shih |
|---|---|
| Rok vydání: | 2000 |
| Předmět: |
Blood Glucose
Male medicine.medical_specialty medicine.medical_treatment White adipose tissue Carbohydrate metabolism Piperazines Mice Internal medicine medicine Animals Hypoglycemic Agents Insulin Pharmacology Glucose tolerance test medicine.diagnostic_test business.industry Imidazoles Glucose Tolerance Test Lipid Metabolism Compound s Metformin Endocrinology Basal (medicine) Lipogenesis Mice Inbred CBA Female Insulin Resistance business medicine.drug |
| Zdroj: | General Pharmacology: The Vascular System. 34:183-191 |
| ISSN: | 0306-3623 |
| Popis: | Acute S 22068 (24 mg/kg po) improved glucose tolerance and increased insulin sensitivity, assessed as the acute blood glucose response to exogenous insulin. The same acute dose did not stimulate insulin secretion or induce hypoglycemia in fed animals. Comparison of acute S 22068 to equipotent doses (with respect to effect on glucose tolerance) of gliclazide (2 mg/kg) and metformin (60 mg/kg) found S 22068 to be similar to metformin with respect to its effects on basal glucose levels (BGL) and insulin sensitivity. This also suggests that S 22068 acts by a mechanism which does not involve insulin release. Acute or sub-chronic S 22068 (14 days at 25 mg/day) had no effect on brown adipose tissue (BAT) or white adipose tissue (WAT) lipogenesis, an insulin-sensitive metabolic pathway. Sub-chronic treatment with S 22068 did not alter body weight (BW) or food intake, and resulted in tolerance to its effects on glucose metabolism and insulin sensitivity. These findings suggest that S 22068 is similar in effect to metformin, and is not insulinogenic, in contrast to the sulfonylureas or putative I 3 imidazoline site ligands. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect